Targeted Therapeutics in Melanoma
Price: 787,50 lei
Availability: in supplier's stock
Author: Gajewski, Thomas F.; Hodi, F. Stephen (Eds.)
ISBN: 978-1-61779-406-3
Publisher: Springer Nature
Publishing Year: 2012
Pages: 377
Category: DERMATOLOGY & COSMETIC SURGERY
DESCRIPTION
Describes both established signal transduction inhibitors as well as emerging molecularly-guided immunotherapies
Places exciting developments in basic biological understanding into a practical clinical context
The first book on melanoma devoted entirely to targeted therapeutics
Includes the most up-to-date data from current clinical Phase I-III trials
Written by high-profile authors representing the world’s leaders in their field
Melanoma is an increasingly important public health problem. Although the cause of most malignant melanomas – over-exposure to ultraviolet light – is well known, effective treatment has remained challenging.
The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics. This book describes these ground-breaking discoveries and their implications for clinical use. As melanoma biology is increasingly understood, so the development of targeted therapies for this disease is spurred ahead. This book covers both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies.
This benchmark book provides the most up-to-date information on the new breed of melanoma therapies. Composed of the works of major researchers and clinicians, this book offers new insights, novel approaches, and promising data for effective treatment planning. Illuminating the latest advances in the field, it is a solid resource for clinical oncologists, translational scientists, and basic cancer researchers.
Places exciting developments in basic biological understanding into a practical clinical context
The first book on melanoma devoted entirely to targeted therapeutics
Includes the most up-to-date data from current clinical Phase I-III trials
Written by high-profile authors representing the world’s leaders in their field
Melanoma is an increasingly important public health problem. Although the cause of most malignant melanomas – over-exposure to ultraviolet light – is well known, effective treatment has remained challenging.
The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics. This book describes these ground-breaking discoveries and their implications for clinical use. As melanoma biology is increasingly understood, so the development of targeted therapies for this disease is spurred ahead. This book covers both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies.
This benchmark book provides the most up-to-date information on the new breed of melanoma therapies. Composed of the works of major researchers and clinicians, this book offers new insights, novel approaches, and promising data for effective treatment planning. Illuminating the latest advances in the field, it is a solid resource for clinical oncologists, translational scientists, and basic cancer researchers.
Book categories
-Special order
-Publishers
-Promo
-Callisto Publications
-New books
-- 1606,50 leiMRP: 1890,00 lei
- 396,90 leiMRP: 441,00 lei
- 981,75 leiMRP: 1155,00 lei
Promotions
-- 1606,50 leiMRP: 1890,00 lei
- 396,90 leiMRP: 441,00 lei
- 981,75 leiMRP: 1155,00 lei
OUR VISITORS OPINIONS